Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2019-03-17 Share Issue/Capital Cha…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Appendix 3B and Notice Under Section 708A 13 pages 310.0KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including ordinary shares and unlisted options. It references ASX rules and provides specifics on the number of securities issued, exercise prices, expiry dates, shareholder approvals, and quotation requests. The content is consistent with a formal announcement of new share issues and related capital changes rather than a full financial report or earnings release. The document is lengthy (15,000 characters) and contains detailed data about the securities issuance, which aligns with the category of Share Issue/Capital Change announcements. Therefore, the appropriate classification is 'SHA' for Share Issue/Capital Change.
2019-03-17 English
Details of Company Address 2 pages 126.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX/Media Release dated 13 March 2019 announcing a change of the company's registered office address. It contains no financial data, no discussion of financial results, no regulatory certifications, or detailed report content. The document is short (2556 characters) and serves as a formal announcement of a corporate administrative change. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it does not mention any report being published or attached. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into any other specific category.
2019-03-12 English
Opinion Leaders Present Botanix Data at AAD 2019 2 pages 489.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX/Media Release dated 4 March 2019, announcing that key opinion leaders presented Botanix Pharmaceuticals' clinical data at the American Academy of Dermatology meeting. It highlights clinical program updates, meetings with potential partners, and general company information. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or interim reports. The document serves as a corporate announcement about clinical data presentations and company progress rather than a formal financial or regulatory report. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as a media release that does not fit other specific categories.
2019-03-03 English
Updated Investor Presentation 20 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is an ASX/Media Release dated 4 March 2019 from Botanix Pharmaceuticals. It is titled 'Updated investor presentation' and contains detailed information about the company's clinical trials, product pipeline, market outlook, and technology platform. The content is structured as a presentation with multiple slides covering clinical programs, market data, and study timelines. There is no indication that this is a full financial report, audit report, or earnings release. Instead, it is a detailed presentation aimed at investors and shareholders to update them on the company's progress and strategy. The document length is about 15,000 characters, consistent with a detailed presentation rather than a brief announcement. Therefore, the most appropriate classification is 'Investor Presentation' (IP).
2019-03-03 English
Half Yearly Report and Accounts 25 pages 401.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half-yearly report' and explicitly states it is for the half-year ended 31 December 2018. It contains detailed financial statements such as the consolidated statement of profit or loss, statement of financial position, and notes to the financial statements. It also includes a directors' report, auditor's independence declaration, and an independent auditor's review report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content and structure align with an Interim / Quarterly Report, which covers a period shorter than a full fiscal year and includes substantive financial data and analysis. Therefore, the document is classified as an Interim / Quarterly Report (IR).
2019-02-27 English
Appendix 3B 12 pages 293.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, issue price, purpose, and compliance with ASX rules. It includes sections on security holder approvals, quotation of securities, and calculation of placement capacity under ASX rules 7.1 and 7.1A. The content is regulatory in nature, focused on announcing and applying for quotation of additional securities rather than providing financial results or management commentary. The document is a formal announcement related to capital raising and securities issuance, consistent with the definition of a Capital/Financing Update (CAP). It is not an annual report, earnings release, or other financial report type, nor is it a proxy, AGM material, or legal proceeding. Therefore, the correct classification is Capital/Financing Update (CAP).
2019-02-27 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.